Piromelatine: Phase II started

Neurim began the double-blind, placebo-controlled, U.S. Phase II ReCOGNITION trial to evaluate 5, 20 and 50 mg oral piromelatine once daily for 26 weeks in about 500 patients treated with stable doses...